| __timestamp | Apellis Pharmaceuticals, Inc. | CRISPR Therapeutics AG |
|---|---|---|
| Wednesday, January 1, 2014 | 8379522 | 1513000 |
| Thursday, January 1, 2015 | 13730311 | 12573000 |
| Friday, January 1, 2016 | 22978599 | 42238000 |
| Sunday, January 1, 2017 | 40303878 | 69800000 |
| Monday, January 1, 2018 | 105285576 | 113773000 |
| Tuesday, January 1, 2019 | 220968770 | 179362000 |
| Wednesday, January 1, 2020 | 299921000 | 266946000 |
| Friday, January 1, 2021 | 420869000 | 438633000 |
| Saturday, January 1, 2022 | 387236000 | 461645000 |
| Sunday, January 1, 2023 | 354387000 | 387332000 |
| Monday, January 1, 2024 | 320653000 |
Unleashing insights
In the ever-evolving landscape of biotechnology, research and development (R&D) spending is a critical indicator of innovation and future growth. Over the past decade, Apellis Pharmaceuticals and CRISPR Therapeutics have been at the forefront of this race. From 2014 to 2023, both companies have significantly increased their R&D investments, reflecting their commitment to pioneering advancements in medical science.
Apellis Pharmaceuticals saw a staggering increase in R&D expenses, growing from a modest $8.4 million in 2014 to a peak of $420 million in 2021. Meanwhile, CRISPR Therapeutics, known for its groundbreaking gene-editing technologies, ramped up its spending from $1.5 million in 2014 to $462 million in 2022, marking a 30,500% increase. This financial commitment underscores the fierce competition and the relentless pursuit of innovation in the biotech sector.
Analyzing R&D Budgets: Merck & Co., Inc. vs Apellis Pharmaceuticals, Inc.
R&D Spending Showdown: Intra-Cellular Therapies, Inc. vs Apellis Pharmaceuticals, Inc.
Ascendis Pharma A/S vs CRISPR Therapeutics AG: Strategic Focus on R&D Spending
Who Prioritizes Innovation? R&D Spending Compared for Madrigal Pharmaceuticals, Inc. and Apellis Pharmaceuticals, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Opthea Limited and CRISPR Therapeutics AG
Analyzing R&D Budgets: Verona Pharma plc vs CRISPR Therapeutics AG
R&D Spending Showdown: Apellis Pharmaceuticals, Inc. vs Arrowhead Pharmaceuticals, Inc.
Apellis Pharmaceuticals, Inc. vs Dynavax Technologies Corporation: Strategic Focus on R&D Spending
Research and Development Investment: Apellis Pharmaceuticals, Inc. vs Celldex Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Apellis Pharmaceuticals, Inc. and Xencor, Inc.
Comparing Innovation Spending: CRISPR Therapeutics AG and Veracyte, Inc.
Research and Development: Comparing Key Metrics for CRISPR Therapeutics AG and Bausch Health Companies Inc.